MedTrace Logo

Influence of Valproic Acid on Extinction-based Therapy in Patients With Fear of Spiders.

NCT02789813 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2018-10-02

No results posted yet for this study

Summary

The purpose of this study is to evaluate whether valproic acid in combination with fear memory reactivation is useful to enhance treatment stability of exposure therapy for specific phobia.

Conditions

  • Phobia, Specific

Interventions

DRUG

Valproic Acid

Once oral administration of 500mg before exposure therapy.

DRUG

Placebo

Once oral administration of 500mg before exposure therapy.

BEHAVIORAL

Fear reactivation

Fear reactivation before exposure therapy.

BEHAVIORAL

No fear reactivation

No fear reactivation before exposure therapy.

Sponsors & Collaborators

  • Prof. Dominique de Quervain, MD

    lead OTHER

Principal Investigators

  • Dominique JF de Quervain, MD · University of Basel

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2018-06-30
Completion
2018-06-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02789813 on ClinicalTrials.gov